Proteolysis of tau by granzyme A in tauopathies generates fragments that are aggregation prone

• Published in: Biochemical journal Vol. 481; no. 18; p. 1255
• Main Authors: Quinn, James P, Fisher, Kate, Corbett, Nicola, Warwood, Stacey, Knight, David, Kellett, Katherine A B, Hooper, Nigel M
• Format: Journal Article
• Language: English
• Published: England 18.09.2024
• Subjects: Brain - metabolism; Brain - pathology; CD8-Positive T-Lymphocytes - metabolism; Granzymes - genetics; Granzymes - metabolism; Humans; Protein Aggregation, Pathological - genetics; Protein Aggregation, Pathological - metabolism; Proteolysis; tau Proteins - genetics; tau Proteins - metabolism; Tauopathies - genetics; Tauopathies - metabolism; Tauopathies - pathology; protease; tauopathy; granzyme; tau proteins; Alzheimers disease
• DOI: 10.1042/BCJ20240007

Tauopathies, including Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy, are characterised by the aggregation of tau into insoluble neurofibrillary tangles in the brain. Tau is subject to a range of post-translational modifications, including proteolysis, that can promote its aggregation. Neuroinflammation is a hallmark of tauopathies and evidence is growing for a role of CD8+ T cells in disease pathogenesis. CD8+ T cells release granzyme proteases but what role these proteases play in neuronal dysfunction is currently lacking. Here, we identified that granzyme A (GzmA) is present in brain tissue and proteolytically cleaves tau. Mass spectrometric analysis of tau fragments produced on digestion of tau with GzmA identified three cleavage sites at R194-S195, R209-S210 and K240-S241. Mutation of the critical Arg or Lys residues at the cleavage sites in tau or chemical inhibition of GzmA blocked the proteolysis of tau by GzmA. Development of a semi-targeted mass spectrometry approach identified peptides in tauopathy brain tissue corresponding to proteolysis by GzmA at R209-S210 and K240-S241 in tau. When expressed in cells the GzmA-cleaved C-terminal fragments of tau were highly phosphorylated and aggregated upon incubation of the cells with tauopathy brain seed. The C-terminal fragment tau195-441 was able to transfer between cells and promote aggregation of tau in acceptor cells, indicating the propensity for such tau fragments to propagate between cells. Collectively, these results raise the possibility that GzmA, released from infiltrating cytotoxic CD8+ T cells, proteolytically cleaves tau into fragments that may contribute to its pathological properties in tauopathies.